# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k170293   
B. Purpose for Submission: Adding a previously cleared test (Emit II Plus Cocaine Metabolite Assay) to the Beckman Coulter DxC 700 AU Clinical Chemistry Analyzer   
C. Measurand: Benzoylecgonine   
D. Type of Test: Qualitative and semi-quantative homogenous enzyme immunoassay   
E. Applicant: Siemens Healthcare Diagnostics, Inc.   
F. Proprietary and Established Names: Emit II Plus Cocaine Metabolite Assay

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DIO - Cocaine and cocainemetabolic test system</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.3250</td><td rowspan=1 colspan=1>91 - Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indication(s) for use below.

2. Indication(s) for use:

The Emit II Plus Cocaine Metabolite Assay is a homogeneous enzyme immunoassay with a $1 5 0 ~ \mathrm { { n g / m L } }$ or $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff. The assay is intended for use in the qualitative and semiquantitative analyses of benzoylecgonine (cocaine metabolite) in human urine. Emit II Plus assays are designed for use with a number of chemistry analyzers.

The Emit II Plus Cocaine Metabolite Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.

3. Special conditions for use statement(s): For Prescription use only.

4. Special instrument requirements: Performance data was obtained using Beckman Coulter DxC 700 AU Clinical Chemistry Analyzer

# I. Device Description:

The Emit II Plus Cocaine Metabolite Assay consists of two ready-to-use reagents:

Antibody/Substrate Reagent 1 consists of sheep polyclonal antibodies to benzoylecgonine $( 2 . 2 \mu \mathrm { g / m L } )$ , bovine serum albumin, G6P $( 1 5 \mathrm { m M } )$ , NAD $( 1 2 \mathrm { m M } )$ , preservatives, and stabilizers. Enzyme Reagent 2 consists of Benzoylecgonine labeled with bacterial G6PDH $( 0 . 4 6 \mathrm { U / m L } )$ ), HEPES buffer, bovine serum albumin, preservatives, and stabilizers.

Materials that are required but thar are sold separately include the following:

· Emit Calibrators/Controls with concentrations of (0, 150, 300, 500 and $1 0 0 0 ~ \mathrm { { n g / m L } ) }$ ). · Commercial controls two levels with concentrations of (0 and $1 0 0 0 ~ \mathrm { { n g / m L } }$ )

# J. Substantial Equivalence Information:

1. Predicate device name(s): Emit II Plus Cocaine Metabolite Assay

2. Predicate 510(k) number(s): k993988

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Emit II Plus CocaineMetabolite Assay(Candidate)</td><td rowspan=1 colspan=1>Emit II Plus CocaineMetabolite AssayPredicate k993988</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For the qualitative and semiquantitativedetermination of the presence ofbenzoylecgonine in human urine</td></tr><tr><td rowspan=1 colspan=1>Measurant</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Benzoylecgonine</td></tr><tr><td rowspan=1 colspan=1>Type of Test</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Qualitative and semi-quantitativehomogeneous enzyme immunoassay</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Sheep polyclonal</td></tr><tr><td rowspan=1 colspan=1>Reagent Form</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Liquid, ready to use</td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Antibody/Substrate Reagent 1Sheep polyclonal antibodies tobenzoylecgonine (2.2 µg/mL), bovineserum albumin, G6P (15 mM), NAD (12mM), preservatives, and stabilizersEnzyme Reagent 2Benzoylecgonine labeled with bacterialG6PDH (0.46 U/mL), HEPES buffer,bovine serum albumin, preservatives, andstabilizers</td></tr><tr><td rowspan=1 colspan=1>Cutoff/controls</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>150ng/mL (±25%)300 ng/mL (±25%)</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human Urine</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Difference</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Emit II Plus CocaineMetabolite AssayCandidate</td><td rowspan=1 colspan=1>Emit II Plus CocaineMetabolite Assayk993988 Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Beckman CoulterDxC 700 AU ClinicalChemistry Analyzer</td><td rowspan=1 colspan=1>SYVA 30R Biochemical System</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline – Third Edition CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline   
· CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition CLSI EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition   
· CLSI EP12-A2, User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline – Second Edition   
· CLSI EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline

# L. Test Principle:

The Emit II Plus Cocaine Metabolite Assayis is based on competition between free drug in the specimen and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH), for antibody binding sites. G6PDH enzyme activity decreases upon binding to the antibody, so the drug concentration in the specimen is proportional to G6PDH activity. The G6PDH enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, which can be measured as an absorbance change spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were conducted in accordance with CLSI EP05-A3. Testing was performed for twenty (20) days with two (2) runs per day, two (2) replicates per run for a total of $\mathrm { n } = 8 0$ sample replicates per test concentration. Nine (9) drug-free negative urine samples were spiked with benzolecogonine to concentrations of $\pm 2 5 \%$ , $\pm 5 0 \%$ , $\pm 7 5 \%$ , and $\pm 1 0 0$ of each cutoff, as well as a zero drug concentration sample. The results are provided below, as determined in qualitative and semi-quantitative modes using each of the $1 5 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ cutoffs:

<table><tr><td rowspan=1 colspan=4>Qualitative Analysis (for 150 ng/mL cutoff)</td></tr><tr><td rowspan=1 colspan=1>Concentration(ng/mL)</td><td rowspan=1 colspan=1>% of cutoff</td><td rowspan=1 colspan=1># of determinations</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg/ 0 Pos</td></tr><tr><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg/ 0 Pos</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9 Neg/!71 Pos</td></tr><tr><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos/ 0 Neg</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos0 Neg</td></tr><tr><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos0 Neg</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos / 0 Neg</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Semi-Quantitative Analysis (for 150 ng/mL cutoff)</td></tr><tr><td rowspan=1 colspan=1>Concentration (ng/mL)</td><td rowspan=1 colspan=1>% of cutoff</td><td rowspan=1 colspan=1># of determinations</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Neg / 0 Pos</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9 Neg / 71 Pos</td></tr><tr><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos / 0 Neg</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos / 0 Neg</td></tr><tr><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos / 0 Neg</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Pos / 0 Neg</td></tr></table>

<table><tr><td colspan="4" rowspan="1">Qualitative Analysis (for 300 ng/mL cutoff)</td></tr><tr><td colspan="1" rowspan="1">Concentration (ng/mL)</td><td colspan="1" rowspan="1">% of cutoff</td><td colspan="1" rowspan="1"># of determinations</td><td colspan="1" rowspan="1">Results</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">-100</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">-75</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">-50</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">-25</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Cutoff</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">54 Neg26 Pos</td></tr><tr><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">+25</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos /0 Neg</td></tr><tr><td colspan="1" rowspan="1">450</td><td colspan="1" rowspan="1">+50</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos /0 Neg</td></tr><tr><td colspan="1" rowspan="1">525</td><td colspan="1" rowspan="1">+75</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos //0 Neg</td></tr><tr><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">+100</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos / 0 Neg</td></tr><tr><td colspan="4" rowspan="1">Semi-Quantitative Analysis (for 300ng/mL cutoff)</td></tr><tr><td colspan="1" rowspan="1">Concentration (ng/mL)</td><td colspan="1" rowspan="1">% of cutoff</td><td colspan="1" rowspan="1"># of determinations</td><td colspan="1" rowspan="1">Results</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">-100</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg / 0 Pos</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">-75</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">-50</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">-25</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Neg0 Pos</td></tr><tr><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Cutoff</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">54 Neg26 Pos</td></tr><tr><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">+25</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos /0 Neg</td></tr><tr><td colspan="1" rowspan="1">450</td><td colspan="1" rowspan="1">+50</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos /0 Neg</td></tr><tr><td colspan="1" rowspan="1">525</td><td colspan="1" rowspan="1">+75</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos /0 Neg</td></tr><tr><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">+100</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">80 Pos / 0 Neg</td></tr></table>

# $b$ . Linearity/assay reportable range:

Recovery studies were conducted in accordance with CLSI EP 6-A in the semiquantitative mode using spiked drug-free urine sample pools with known concentrations of benzoylecgonine to generate eleven (11) dilutions to achieve concentrations ranging from $5 0 ~ \mathrm { n g / m L }$ to $1 0 0 0 ~ \mathrm { { n g / m L } }$ . Each concentration was tested in five replicates and drug recovery was calculated using the mean concentration of the five replicates. The results are summarized below:

<table><tr><td rowspan=1 colspan=3>Linearity/Recovery</td></tr><tr><td rowspan=1 colspan=1>Expected Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean Concentration(ng/mL)</td><td rowspan=1 colspan=1>Mean Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>106.1%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>103.1%</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>100.2%</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>104.3%</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>99.3%</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>380</td><td rowspan=1 colspan=1>100.4%</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>543</td><td rowspan=1 colspan=1>108.6%</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>792</td><td rowspan=1 colspan=1>105.6%</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>906</td><td rowspan=1 colspan=1>100.6%</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>1029</td><td rowspan=1 colspan=1>102.9%</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The Emit II Plus Cocaine Metabolite Assay Calibrators and Controls were previously cleared in k993755.

d. Detection limit:

Not Applicable

# e. Analytical specificity:

For analytical specificity please reference k993988. Additional structurally related compounds were evaluated by spiking each of the drugs indicated in the tables below into drug free urine, and determining the lowest concentration that produces a response equivalent to benzoylecgonine at each device cutoff.

Structurally Related Compounds, $1 5 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration (ng/mL) thatgenerates responseapproximately equivalent tothe cutoff</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Ecgonine*</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>3%</td></tr><tr><td rowspan=1 colspan=1>Cocaine*</td><td rowspan=1 colspan=1>29,000</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>Norcocaine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr><tr><td rowspan=1 colspan=1>Cocaethylene</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr><tr><td rowspan=1 colspan=1>Ecgonine methylester</td><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr></table>

Structurally Related Compounds, $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration (ng/mL)thatgenerates responseapproximately equivalentto the cutoff</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Ecgonine*</td><td rowspan=1 colspan=1>15,000</td><td rowspan=1 colspan=1>2%</td></tr><tr><td rowspan=1 colspan=1>Cocaine*</td><td rowspan=1 colspan=1>61,000</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>Norcocaine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr><tr><td rowspan=1 colspan=1>Cocaethylene</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr><tr><td rowspan=1 colspan=1>Ecgonine methyl ester</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt;0.01%</td></tr></table>

\*Ecgonine and cocaine tested at the concentrations above produced a result approximately equivalent to the cutoff.

Benzoylecgonine glucuronide, a metabolite of benzoylecgonine, shares structural similarities to benzoylecgonine has significant cross reactivity to the Emit II Plus Cocaine Metabolite Assay. This cross reactivity was observed in the method comparison study, where the presence of Benzoylecgonine-glucuronide produced a positive result when insufficient levels of benzoylecgonine were present to produce a positive result.

Laboratories who use this assay should use caution when confirming positive results. Confirmatory methods that do not detect benzoylecgonine glucuronide may not match the initial screening assay results (see method comparison results below).

f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentrations of $1 5 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ is described in the precision section, M.1.a. above

2. Comparison studies:

# a. Method comparison with predicate device:

Method comparison was conducted in accordance with CLSI EP09-A3 and CLSI EP12-A2. Benzoylecgonine values of native patient urine samples were determined and were compared to the results obtained by a comparator Gas Chromatography/Mass Spectrometry (GC/MS) method. Results were obtained in both qualitative and semi-quantitative modes, and are summarized below:

Method Comparison Results for the $1 5 0 ~ \mathrm { { n g / m L } }$ Cutoff $( \mathtt { n } = 1 0 2 )$

<table><tr><td rowspan=1 colspan=4>GC/MS</td></tr><tr><td rowspan=1 colspan=1>Negative(&lt;75 ng/mL)</td><td rowspan=1 colspan=1>Negative(75-149 ng/mL)</td><td rowspan=1 colspan=1>Positive(150 - 225ng/mL)</td><td rowspan=1 colspan=1>Positive(&gt; 225ng/mL)</td></tr></table>

<table><tr><td rowspan=1 colspan=6>Qualitative</td></tr><tr><td rowspan=2 colspan=1>DxC700AU</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=6>Semi-Quantitative</td></tr><tr><td rowspan=2 colspan=1>DxC 700AU</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Discordant Results, 150ng/mL Cutoff, Qualitative and Semi-quantitative mode</td></tr><tr><td rowspan=1 colspan=1>Emit II Plus Cocaine Metabolite Assay(Pos/Neg)</td><td rowspan=1 colspan=1>GC/MS concentration (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>124</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>73</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>83</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>75</td></tr></table>

\*All samples are found to contain conjugated Benzolecgnine glucuronide molecule which shares structural similarities to Benzolecgonine and positive interference to the Emit II Plus Cocaine Metabolite Assay. Benzoylecgonine glucuronide, a metabolite of benzoylecgonine, shares structural similarities to benzoylecgonine and has significant cross reactivity to the Emit II Plus Cocaine Metabolite Assay. This cross reactivity produced a positive result when insufficient levels of benzoylecgonine were present to produce a positive result. When specimens were treated with glucuronidase, the concentraton of benzoylecgonine in the sample was within $+ / -$ $50 \%$ of the cutoff.

Method Comparison Results for the $3 0 0 ~ \mathrm { { n g / m L } }$ Cutoff $( \mathtt { n } = 9 5 )$ \*All samples are found to contain conjugated Benzolecgnine glucuronide molecule which shares structural similarities to Benzolecgonine and positive interference to the Emit II Plus Cocaine Metabolite Assay. Benzoylecgonine glucuronide, a metabolite of benzoylecgonine, shares structural similarities to benzoylecgonine and has significant cross reactivity to the Emit II Plus Cocaine Metabolite Assay. This cross reactivity produced a positive result when insufficient levels of benzoylecgonine were present to produce a positive result. When specimens were treated with glucuronidase, the concentraton of benzoylecgonine in the sample was within $+ / .$ - $50 \%$ of the cutoff.

<table><tr><td rowspan=1 colspan=4>GC/MS</td></tr><tr><td rowspan=1 colspan=1>Negative( &lt;150 ng/mL)</td><td rowspan=1 colspan=1>Negative(150-299 ng/mL)</td><td rowspan=1 colspan=1>Positive(300-450 ng/mL)</td><td rowspan=1 colspan=1>Positive(&gt; 450ng/mL)</td></tr></table>

<table><tr><td rowspan=1 colspan=6>Qualitative</td></tr><tr><td rowspan=2 colspan=1>DxC 700AU</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=6>Semi-Quantitative</td></tr><tr><td rowspan=2 colspan=1>DxC700AU</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Discordant Results, 300ng/mL Cutoff, Qualitative and Semi-quantitative mode</td></tr><tr><td rowspan=1 colspan=1>Emit II Plus Cocaine Metabolite Assay(Pos/Neg)</td><td rowspan=1 colspan=1>GC/MS concentration (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>217</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>173</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>207</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>233</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>143</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>217</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>173</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>232</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>157</td></tr><tr><td rowspan=1 colspan=1>*Positive</td><td rowspan=1 colspan=1>234</td></tr></table>

# b. Matrix comparison:

Only Urine samples are recommended for use with this assay.

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Apllicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: Not Applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.